Paul Frohna Email & Phone Number

United States

• Provide CMO consulting services for early stage biotech companies across multiple therapeutic areas including oncology/immuno-oncology, fibrosis, immunology, neurology/neurodegeneration, and infectious diseases.• Support corporate fund-raising activities with VCs and strategic investors, including creating and presenting pitch decks.• Hands on approach for the development and review of scientific documents, protocols, and regulatory dossiers (Pre-IND, IND, and CTA) for North America, UK, EU, and Australia.

Genova, It

IAMA is pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of individuals suffering from brain disorders.IAMA is building a leading, next-generation neuroscience pipeline based on advances in drug discovery and neurobiology.

Accure is a Barcelona-based, clinical-stage private biotech developing first-in-class neurotherapeutics. Accure Therapeutics is working to find new Disease Modifying Therapies for Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy. We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research.

San Diego, Us

Endeavor BioMedicines, Inc., is a clinical stage company targeting the drivers of fibrosis and oncology. Our lead program, ENV-101, is a Hedgehog signalling inhibitor currently in ex-US Phase 2 studies for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis (WHISTLE-PF Trial). A second asset, HER3-targeted ADC for multiple solid tumor indications, was recently in-licensed from Hummingbird Biosciences and we filed an IND in July 2024. I built and led exceptional clinical advisory boards for lung fibrosis and HER3-expressing solid tumors. Responsible for translational medicine, clinical operations, pharmacovigilance and biostatistics.

As CMO/CSO, responsible for all Discovery, Research, & Development activities, personnel, and budgets to develop novel cancer and infectious disease immunotherapeutics targeting the butyrophylins (BTNs), a next generation family of checkpoint molecules. Participated in Series B in 2019 ($60M) and led the Series C discussions, data presentations, and due diligence process in 2022 ($100M). Oversee scientific inlicensing and partnership activities.Designed the Phase 1/2 adaptive design for testing ICT-01, alone and in combination, in patients with relapsed/refractory solid and liquid tumors, with multiple oral presentations at AACR, SITC, and ESMO.

Denver, Colorado, Us

Responsible for the clinical, biometrics, and regulatory affairs activities to support the development of the company's portfolio of novel multi-cytokine inhibitors for immuno-oncology and immune-mediated diseases. Established KOL networks and clinical advisory boards for hematologic malignancies, alopecia areata, and celiac disease. Member of the executive team responsible for corporate portfolio planning, fund-raising and licensing/partnerships.

Responsible for overseeing the translational medicine, safety and clinical development of the portfolio of small molecules and biologics currently being developed in relapsing multiple sclerosis (RMS), inflammatory bowel disease, and eosinophilic esophagitis. Serving as medical lead for the Phase 2 & 3 RADIANCE & SUNBEAM trials in RMS that recently reported positive Phase 2&3 results http://www.marketwatch.com/story/receptos-reports-positive-phase-2-results-for-rpc1063-in-relapsing-multiple-sclerosis-2014-06-09. Building an early development group responsible for transitioning internal research programs in T2DM/NASH and immunology into the clinic. Participated on partnering/acquisition team and focused on inlicensing development stage assets in inflammation/immunology and neuroscience.

Identify current topics in the field of hematology for the annual meeting and appropriate speakers with the necessary expertise to address these topics with cutting edge knowledge and understanding for the AISH 2012 and AISH 2013 meetings. http://www.bitlifesciences.com/aish2013/programcommittee.asp

Responsible for U.S. and EU clinical development of Raplixa for surgical bleeding. Successfully completed international Phase 1 to Phase 3 trials in 3.5 yrs that resulted in the filing of an MAA in the EU in October 2013 and a BLA filing in Q1 2014, with approvals in 2015.

Designed translational medicine programs for MSC program for spinal cord injury and stroke until the company ran into financial difficulty, resulting in a return to medical tourism.

San Francisco, Ca, Us

Responsible for Clinical Research, Data Management, Biostatistics, Drug Safety and Clinical Pharmacology.

Responsible for rebuilding the early development arm of CV Therapeutics following a massive re-organization, with the responsibility of moving multiple projects out of research and into the clinic.

South San Francisco, California, Us

Clinical lead for Rituxan Phase 2 program for relapsing and primary progressive MS. Patented the use of B-cell depleting therapy for MS, which led to the ocrelizumab program that was successful in Phase 3 trials for RMS and PPMS in 2015. Project team leader for two immunology programs targeting LFA-1 and alpha-4 integrin for psoriasis and MS, respectively. Responsible for the clinical pharmacology programs for the Tarceva and Raptiva FDA filings, and the label expansion Herceptin projects.

Pharmacy, Pharmacy

Doctor Of Medicine (M.D.), Internal Medicine

Graduate Studies In Epidemiology & Clinical Research

Doctor Of Philosophy (Ph.D.), Neuropharmacology